Literature DB >> 10747821

Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture.

A Giacometti1, O Cirioni, F Barchiesi, F Ancarani, G Scalise.   

Abstract

The in vitro activity of nitazoxanide alone and in combination with azithromycin and rifabutin was investigated against four clinical isolates of Cryptosporidium parvum. The susceptibility tests were performed by inoculation of the isolates on toe cell monolayers and determination of the parasite count after 48 h incubation at 37 degrees C. The culture medium was supplemented with Dulbecco's modified Eagle's medium containing serial dilutions of each agent. Antibiotic-free plates were used as controls. Experiments were performed in triplicate. Nitazoxanide showed moderate anticryptosporidial activity: it suppressed the growth of parasites by >50% at 8 mg/L. A parasite reduction of 79.8-83.9% was observed when nitazoxanide 8 mg/L was combined with azithromycin 8 mg/L and rifabutin 8 mg/L. The study suggests that nitazoxanide may be active in inhibiting C. parvum growth in vitro upon combination with azithromycin or rifabutin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10747821     DOI: 10.1093/jac/45.4.453

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.

Authors:  William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

2.  In vitro evaluation of the effectiveness of the macrolide rokitamycin and chlorpromazine against Acanthamoeba castellanii.

Authors:  A Mattana; G Biancu; L Alberti; A Accardo; G Delogu; P L Fiori; P Cappuccinelli
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

Review 3.  Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Authors:  Vanessa R Anderson; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.

Authors:  Hayley Sparks; Gayatri Nair; Alejandro Castellanos-Gonzalez; A Clinton White
Journal:  Curr Trop Med Rep       Date:  2015-08-01

5.  Diarrhea in patients with AIDS.

Authors:  Susan C Morpeth; Nathan M Thielman
Journal:  Curr Treat Options Gastroenterol       Date:  2006-02

6.  Resolution of Cryptosporidiosis in Transplant Recipients: Review of the Literature and Presentation of a Renal Transplant Patient Treated With Nitazoxanide, Azithromycin, and Rifaximin.

Authors:  Ewa Tomczak; April N McDougal; A Clinton White
Journal:  Open Forum Infect Dis       Date:  2021-12-04       Impact factor: 3.835

Review 7.  Cryptosporidium infection in solid organ transplantation.

Authors:  Diana F Florescu; Uriel Sandkovsky
Journal:  World J Transplant       Date:  2016-09-24

8.  The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis.

Authors:  Sangun Lee; Melanie Harwood; Don Girouard; Marvin J Meyers; Mary A Campbell; Gillian Beamer; Saul Tzipori
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

9.  Assessment of Giardia and Cryptosporidium Assemblages/Species and Their Viability in Potable Tap Water in Beni-Suef, Egypt Using Nested PCR/RFLP and Staining.

Authors:  Doaa Hamdy; Ayman El-Badry; Wegdan Abd El Wahab
Journal:  Iran J Parasitol       Date:  2019 Jul-Sep       Impact factor: 1.012

10.  Nitazoxanide Exerts Immunomodulatory Effects on Peripheral Blood Mononuclear Cells from Type 2 Diabetes Patients.

Authors:  Mauricio Castillo-Salazar; Fausto Sánchez-Muñoz; Rashidi Springall Del Villar; Gabriel Navarrete-Vázquez; Adrián Hernández-DiazCouder; Carlos Mojica-Cardoso; Sara García-Jiménez; Cairo Toledano-Jaimes; Germán Bernal-Fernández
Journal:  Biomolecules       Date:  2021-12-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.